FDA database queried October 8, 2026. Verify at FDA
GLP-1 medication shortage tracker
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not in the FDA Drug Shortages database, checked October 8, 2026. Liraglutide (Victoza, Saxenda) is still listed. Every status below links to the FDA record it came from.
No insurance needed. Two cash programs to check.
- Check price →
- Check price →SnagRx's homepage shows its 12-month prepaid prices first
SnagRx$99 a monthBilled monthly. The 12-month plan is $69 a month, billed as $828 up front.compounded semaglutide
The two highest-volume GLP-1s, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are no longer in the FDA Drug Shortages database. Both shortages are resolved. Liraglutide remains in active shortage, with Victoza and Saxenda on limited supply as of October 8, 2026.
Current FDA shortage status
Queried from the FDA Drug Shortages Database on October 8, 2026. GLP-1 shortage history counts the records behind each row, molecule by molecule.
| Drug (molecule) | Brand names | FDA status | Last FDA record update | FDA source |
|---|---|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Resolved | June 4, 2026 (most recent record in database, Rybelsus discontinuation notice) | FDA API query |
| Tirzepatide | Mounjaro, Zepbound | Resolved | Not in active database (shortage resolved) | FDA Drug Shortages Database |
| Liraglutide | Saxenda, Victoza | Active Shortage | September 22, 2026 (most recent record update) | FDA API query |
| Dulaglutide | Trulicity | Resolved | Not in active database | FDA Drug Shortages Database |
Source: FDA Drug Shortages Database, queried via openFDA API on October 8, 2026. A “Resolved” status means zero records were returned by the API (NOT_FOUND), which is how FDA represents a resolved or never-listed shortage. Statuses can change; verify at FDA Drug Shortages for the most current information.
Semaglutide (Ozempic, Wegovy, Rybelsus)
Injectable semaglutide (Ozempic, Wegovy) shortage: resolved. The semaglutide injection shortage that began in late 2022 is no longer in the FDA Drug Shortages database. The FDA database queried on October 8, 2026 returned zero records for semaglutide injection. The database did return three records for Rybelsus (semaglutide tablets), but those records carry a “To Be Discontinued” status, not a shortage status. Novo Nordisk is winding down Rybelsus production and replacing it with Ozempic tablets (FDA update date: June 4, 2026).
The semaglutide injection shortage was one of the most-searched drug supply events in recent years. During the shortage, FDA enforcement discretion under Section 503A and 503B of the FD&C Act permitted licensed compounding pharmacies to produce semaglutide copies. The shortage resolution changed that: once FDA removed semaglutide from the active shortage list, routine compounding of semaglutide copies lost its shortage-era legal basis. Individual patient-specific compounding for documented medical need (for instance, an allergy to an excipient in the approved product) may still be lawful, but the broad commercial-scale compounding that occurred during the shortage era is no longer supported by shortage status.
For the compounding picture in full, see compounded vs FDA-approved semaglutide and switching from compounded to brand.
| Product | Form | FDA status | Availability | Last FDA update | Note |
|---|---|---|---|---|---|
| Ozempic (semaglutide injection) | Injection, subcutaneous | Not in active FDA shortage database | Available | October 8, 2026 | Zero records returned by FDA shortages API for semaglutide injection. Shortage resolved. |
| Wegovy (semaglutide injection) | Injection, subcutaneous | Not in active FDA shortage database | Available | October 8, 2026 | Zero records returned by FDA shortages API for semaglutide injection. Shortage resolved. |
| Rybelsus (semaglutide tablet) | Tablet, oral (3 mg, 7 mg, 14 mg) | To Be Discontinued | Being discontinued | June 4, 2026 | Novo Nordisk is ending Rybelsus production. Replacement: Ozempic (semaglutide) tablets. FDA database updated June 4, 2026. NDCs: 0169-4303-30, 0169-4307-30, 0169-4314-30. |
Source: openFDA Drug Shortages API query, October 8, 2026.
Tirzepatide (Mounjaro, Zepbound)
Tirzepatide shortage: resolved. The FDA Drug Shortages database returned zero records for tirzepatide on October 8, 2026. The active shortage, which ran from mid-2023 while Eli Lilly ramped supply for Mounjaro and then Zepbound, has been resolved.
As with semaglutide, the tirzepatide shortage drove a significant compounding market. During the shortage, licensed pharmacies could compound tirzepatide under the shortage exemption. With the shortage resolved, that basis no longer applies at scale. The FDA has moved to restrict routine compounding of tirzepatide, consistent with its standard post-shortage enforcement posture.
For current pricing on both branded and compounded tirzepatide programs, see the program comparison chart and cheapest compounded tirzepatide programs.
| Product | Form | FDA status | Availability | Last FDA update | Note |
|---|---|---|---|---|---|
| Mounjaro (tirzepatide injection) | Injection, subcutaneous | Not in active FDA shortage database | Available | October 8, 2026 | Zero records returned by FDA shortages API. Tirzepatide shortage resolved. |
| Zepbound (tirzepatide injection) | Injection, subcutaneous | Not in active FDA shortage database | Available | October 8, 2026 | Zero records returned by FDA shortages API. Tirzepatide shortage resolved. |
Source: FDA Drug Shortages Database, October 8, 2026.
Liraglutide (Saxenda, Victoza)
Liraglutide shortage: active. Liraglutide remains in the FDA Drug Shortages database, with records from four manufacturers.
Victoza (liraglutide from Novo Nordisk, the diabetes brand) shows Limited Availability due to a delay in shipping, with no estimated recovery date as of October 8, 2026. Saxenda (liraglutide for obesity) shows Limited Availability. Its FDA record gives the reason as discontinuation of the manufacture of the drug and says the product will be available until discontinuation in January 2027. Liraglutide from Hikma, Meitheal and Novo Nordisk (distributed by Teva) shows Available. Teva is discontinuing its own liraglutide product (notice posted May 14, 2026).
Liraglutide is an older GLP-1 (approved 2010 for Victoza, 2014 for Saxenda). It has been largely superseded clinically by semaglutide and tirzepatide, which show greater efficacy.
| Product | Company | FDA status | Availability | Last FDA update | Note |
|---|---|---|---|---|---|
| Victoza (liraglutide injection) | Novo Nordisk | Current shortage | Limited Availability | September 22, 2026 | Shortage reason: delay in shipping. Estimated duration: TBD. FDA record since July 18, 2023. |
| Saxenda (liraglutide injection) | Novo Nordisk | Current shortage | Limited Availability | September 22, 2026 | Shortage reason: discontinuation of the manufacture of the drug. Available until discontinuation in January 2027. Discontinuation notice posted August 25, 2026. NDC 0169-2800-15. |
| Liraglutide Injection (Novo Nordisk, distributed by Teva) | Novo Nordisk | Current | Available | September 22, 2026 | Both packages show Available. FDA record since July 18, 2023. |
| Liraglutide Injection, generic (Hikma) | Hikma Pharmaceuticals USA | Current | Available | September 18, 2026 | Both packages show Available. FDA record since July 18, 2023. |
| Liraglutide Injection, generic (Meitheal) | Meitheal Pharmaceuticals | Current | Available | August 27, 2026 | Both packages show Available. FDA record since July 18, 2023. |
| Liraglutide Injection, generic (Teva) | Teva Pharmaceuticals USA | To Be Discontinued | Being discontinued | May 14, 2026 | Teva is ending production of this formulation. |
Source: openFDA Drug Shortages API query, October 8, 2026. Initial posting date for every Current record: July 18, 2023.
Dulaglutide (Trulicity)
Dulaglutide shortage: not in active database. The FDA Drug Shortages database returned zero records for dulaglutide on October 8, 2026. Trulicity (dulaglutide, Eli Lilly) is not in the active shortage list. Note that Eli Lilly announced in 2024 that it would be winding down Trulicity promotion as the company focuses resources on tirzepatide (Mounjaro, Zepbound). That is a commercial strategy shift, not a drug shortage, and Trulicity remains on the market.
| Product | Form | FDA status | Availability | Last FDA update | Note |
|---|---|---|---|---|---|
| Trulicity (dulaglutide injection) | Injection, subcutaneous | Not in active FDA shortage database | Available | October 8, 2026 | Zero records returned by FDA shortages API. |
Source: FDA Drug Shortages Database, October 8, 2026.
What a shortage means for access and price
A drug shortage is a formal FDA determination under Section 506C of the FD&C Act, not a rumor or a pharmacy stockout. When FDA declares a shortage, it means total supply across all manufacturers has fallen below projected demand. When FDA resolves a shortage, it means supply has recovered to adequate levels. The signal for resolution is removal from the active database.
During the 2022-2025 semaglutide shortage and the 2023-2024 tirzepatide shortage, two things happened simultaneously. First, patients who needed these drugs had a harder time filling prescriptions, as pharmacies rationed supply. Second, the shortage created a legal opening for compounding pharmacies to produce copies of the drugs at lower cost. Compounding activity during the shortage generated the telehealth GLP-1 market that now reaches hundreds of thousands of patients.
The shortage resolution did not eliminate compounded GLP-1s overnight. It narrowed the legal basis. Individual pharmacies and programs adjusted their compliance postures in different ways, some by adding patient-specific customizations that fall under the individual patient exemption, others by transitioning patients to branded alternatives. The legal landscape for compounded GLP-1s remains contested in 2026, with ongoing court cases between compounding trade groups and the FDA. This page covers shortage status, not compounding legality. For the compounding picture, read the compounded vs approved semaglutide explainer.
On price: branded GLP-1s carry list prices of $900 to $1,400 a month without insurance. During the shortage, compounded alternatives offered entry points of $150 to $400 a month. As the shortage ended and the compounding market tightened, some programs raised prices while others maintained pricing through the individual-patient-need route. The program comparison chart tracks current pricing across all options.
If you need the drug but cannot access or afford the branded version, the drug profiles page covers each GLP-1 individually, including manufacturer patient-assistance programs and the paths to access that do not depend on shortage status.
How we source this data
The FDA Drug Shortages database is the authoritative primary source for all statuses on this page. We query the openFDA API directly at api.fda.gov/drug/shortages.json using the drug's generic name as the search term. Each API response includes the manufacturer name, FDA record status, update date, availability note, and the shortage reason code where provided.
We treat zero API results as the resolved-shortage signal, consistent with how FDA operates: the agency removes a drug from the active list after it determines supply is adequate. We do not infer status from news coverage, pharmacy reports, or social media. When no record is found and we are not aware of an active shortage, we mark the status as Resolved and cite the API query.
This page was last queried on October 8, 2026. Drug shortage status can change at any time. If you believe a status on this page is wrong, you can file a correction and we will re-query the FDA database and update within one business day.
Citing the FDA Drug Shortages Database as a factual data source is not an endorsement of any medication by FDA in a selling sense, nor does it imply FDA approval of any compounded alternative. These are public records of supply conditions. Always consult a licensed clinician or pharmacist about your medication access.
Frequently asked questions
Is Ozempic still in shortage?
No. Ozempic (semaglutide injection) is not in the FDA Drug Shortages database as of October 8, 2026. The FDA removes a drug from its active shortage list once it determines supply is adequate. The semaglutide injection shortage that ran from late 2022 has been resolved. Note that Rybelsus (semaglutide tablets) is being discontinued by Novo Nordisk and replaced with Ozempic tablets; that is a product transition, not a shortage.
Is Mounjaro or Zepbound still in shortage?
No. Tirzepatide (Mounjaro and Zepbound) is not in the FDA Drug Shortages database as of October 8, 2026. The active shortage that ran through mid-2024 has been resolved. The FDA removes drugs from the active list once supply is adequate; absence from the database is the resolution signal.
Is there a current liraglutide shortage?
Yes. Liraglutide remains in the FDA Drug Shortages database with active records as of October 8, 2026. Victoza shows Limited Availability due to a delay in shipping, with no estimated recovery date. Saxenda shows Limited Availability because its manufacture is being discontinued. The FDA record says it will be available until January 2027. Liraglutide from Hikma, Meitheal and Novo Nordisk (distributed by Teva) shows as Available.
What does 'shortage resolved' mean for compounding?
When the FDA declared semaglutide and tirzepatide shortages active, federal law (Section 503A of the FD&C Act) permitted licensed pharmacies to compound copies of those drugs for individual patients. When the FDA resolves a shortage and removes the drug from its list, that legal basis narrows significantly. Compounders can still compound for individual patients with a documented clinical need (such as an allergy to an ingredient in the approved product or a dose not commercially available), but the broad shortage-era latitude is gone. For liraglutide, which remains in active shortage, the broader compounding basis persists for the affected formulations.
How does FDA define a drug shortage?
FDA defines a drug shortage as a period in which the total supply of a product or all clinically interchangeable alternatives falls below the level needed to meet current and projected demand. FDA tracks shortages under the Federal Food, Drug, and Cosmetic Act Section 506C. Manufacturers are required to notify FDA at least six months before discontinuing a drug or reducing supply. The FDA Drug Shortages database is the authoritative public record.
Where can I check the live FDA shortage list?
The FDA Drug Shortages database is searchable at the FDA website and via the openFDA API (api.fda.gov/drug/shortages.json). The FDA Drug Shortages database is updated by manufacturers and FDA staff; individual records carry their own update dates. For the most current status of any specific drug, query the live database directly.
Why does a shortage matter for price?
Drug shortages directly affect price in two ways. First, when supply is constrained, retail pharmacies may limit quantities or apply above-list pricing. Second, FDA shortage status determined which compounded alternatives were legally permitted: compounded semaglutide and tirzepatide from telehealth programs grew rapidly during the shortage era and offered substantially lower prices than branded alternatives. As shortages resolved, FDA moved to restrict routine compounding, which narrowed the low-cost compounded option for these drugs.
GLP Chart is a comparison site, not a medical provider or pharmacy. Shortage status is sourced from the FDA Drug Shortages Database queried on October 8, 2026; statuses can change between queries. This information is for general awareness only. Talk to a licensed clinician or pharmacist about your specific medication access.